Cargando…
Dupilumab-Associated Psoriasis and Psoriasiform Manifestations: A Scoping Review
BACKGROUND: Dupilumab is the first approved IL-4Rα inhibitor for the treatment of atopic dermatitis at present with good efficacy and safety. However, there have been several reports of psoriasis and psoriasiform manifestations occurring after dupilumab therapy in recent years, showing a new paradox...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
S. Karger AG
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10407831/ https://www.ncbi.nlm.nih.gov/pubmed/37100035 http://dx.doi.org/10.1159/000530608 |